Physician profile
Meredith Angel
NPI 1053724278
$6,381.32
in general payments reported to CMS, 2019-2025
32 companies · $4,514 in 2025
The $4,514 reported for 2025 was more than what 90% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $96.01 · 2021: $384 · 2022: $217 · 2023: $445 · 2024: $333 · 2025: $4,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $3,417 · Food and Beverage: $1,451 · Travel and Lodging: $324 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $3,416.67 |
| Food and Beverage | $1,451.48 |
| Travel and Lodging | $323.96 |
| Education | $100.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $3,832.85 | 2024-2025 | Nanoknife, Nanoknife |
| Astellas Pharma US INC | $781.06 | 2019-2025 | Myrbetriq, Xtandi |
| Pfizer INC. | $230.97 | 2019-2025 | |
| Janssen Biotech, INC. | $172.25 | 2020-2025 | Erleada |
| C. R. Bard, INC. & Subsidiaries | $147.30 | 2025 | Bard Urinary Drainage Bag |
| Sumitomo Pharma America, INC. | $136.05 | 2023-2025 | Gemtesa, Orgovyx |
| Procept Biorobotics Corporation | $111.33 | 2024 | Aquabeam System |
| 180 Medical, INC. | $108.60 | 2019-2025 | |
| Axonics, INC. | $96.81 | 2020-2024 | Axonics |
| Bayer Healthcare Pharmaceuticals INC. | $74.73 | 2020-2023 | |
| Endo USA, INC. | $65.56 | 2025 | Xiaflex, Aveed |
| Accord Healthcare, INC. | $63.43 | 2022-2025 | |
| Olympus America INC. | $50.14 | 2025 | Bovie, Itind System |
| Allergan, INC. | $48.93 | 2019 | |
| Abbvie INC. | $47.39 | 2021-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $42.91 | 2021 | |
| Urogen Pharma, INC. | $40.56 | 2025 | |
| Boston Scientific Corporation | $39.31 | 2020-2022 | |
| Photocure INC | $35.37 | 2024-2025 | Cysview |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Tempus Ai, INC | $28.54 | 2024 | |
| Laborie Medical Technologies Corp. | $28.09 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $26.92 | 2022-2025 | Exparel |
| Tolmar, INC. | $23.07 | 2024 | |
| Conmed Corporation | $18.94 | 2023 | Airseal |
| Neotract INC. | $18.27 | 2019 | |
| Telix Pharmaceuticals | $17.23 | 2024 | Illuccix |
| Endo Pharmaceuticals INC. | $17.15 | 2021 | |
| Medtronic, INC. | $15.33 | 2022 | |
| Amgen INC. | $14.28 | 2024 | Prolia |
| Dentsply Ih INC. | $12.89 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$48,212.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Angel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.